Vir Biotechnology, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on the stock and has a $20.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Ulz has given his Buy rating due to a combination of factors including the promising developments in Vir Biotechnology’s pipeline. The company has made significant progress with its VIR-5500 program, particularly in the mCRPC indication, where dose escalation studies are ongoing and a comprehensive data update is anticipated in the first quarter of 2026. This update is expected to provide critical insights into safety, efficacy, and durability, which are seen as pivotal for the company’s future growth.
Additionally, the early completion of enrollment in the ECLIPSE-1 trial underscores strong engagement and highlights the unmet need in chronic hepatitis delta, with data from all ECLIPSE trials expected by the first quarter of 2027. The company’s robust cash position further supports its ongoing research and development efforts, providing a solid foundation for continued innovation and potential market expansion. These factors collectively contribute to the positive outlook and the Buy rating for Vir Biotechnology.
According to TipRanks, Ulz is a 4-star analyst with an average return of 4.7% and a 44.57% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Kyverna Therapeutics, Inc., and Rhythm Pharmaceuticals.
In another report released today, Needham also maintained a Buy rating on the stock with a $14.00 price target.